This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary TNFα Therapeutic Antibody Development
Background of TNFα
TNFα is crucial in the development and progression of chronic inflammation, autoimmune diseases, and certain types of cancers in companion animals. Developing therapeutic antibodies targeting TNFα offers new treatment avenues by reducing inflammatory responses. BioVenic provides services for developing veterinary TNFα therapeutic antibodies, encompassing the entire antibody development process to offer more effective treatment options for companion animals like canines and felines.
Background of TNFα
| Full Name | Tumor necrosis factor-alpha |
|---|---|
| Aliases | DIF, TNF, TNF-alpha, TNFA, TNLG1F, TNFSF2. |
| Target Profile | As a pro-inflammatory cytokine belonging to the tumor necrosis factor superfamily, TNFα is primarily produced by activated macrophages. It plays a pivotal role in regulating immune responses, inflammation, cell proliferation, apoptosis, and lipid metabolism by binding to its specific receptors, TNFR1 and TNFR2. |
MoA of TNFα
Upon binding with its receptors TNFR1 and TNFR2, TNF-α activates several signaling pathways that regulate cell survival and death. Activation of TRADD upon TNF-α binding to TNFR1 initiates a cascade of interactions, leading to caspase 3 activation and cell apoptosis. Another pathway through TNFR1 involves TRAF2 recruitment, phosphorylating NF-κB, and mediating the transcription of proteins involved in inflammation and cellular survival. The binding of TNF-α and TNFR1 also activates the MAPK pathway through TRAF2, leading to the activation of c-JNK and the translocation of transcription factors such as AP-1 to the nucleus, triggering cellular responses of apoptosis and survival.
Fig.1 Schematic diagram of TNF-α signaling pathways.1
Application in Veterinary Therapeutics
TNFα is a key mediator in various chronic inflammatory and autoimmune diseases in companion animals, targeted by therapeutic antibodies that specifically bind to TNFα, inhibiting its interaction with receptors TNFR1 and TNFR2. This blockade suppresses the inflammatory and apoptotic signaling pathways triggered by TNFα, effectively controlling the progression of these diseases. Additionally, TNFα contributes to tumor growth and spread in certain cancer types by fostering an inflammatory and immunosuppressive environment. Thus, TNFα antibodies can also serve as an adjunct therapy to inhibit tumor growth and dissemination.
Veterinary TNFα Therapeutic Antibody Development Services
BioVenic offers comprehensive veterinary TNFα therapeutic antibody development services, assisting in providing innovative treatment options for companion animals, particularly when traditional therapies are ineffective or cause side effects. Our services extend from gene synthesis to the final production of antibodies, encompassing design, preparation, purification, and detailed verification of biological activity. We employ advanced technologies such as hybridoma, single B cell, and phage display techniques, ensuring strict quality control throughout the development process. We also offer species-specific antibody development services, catering effectively to the needs of specific companion animal species.
Please click the link below for more information about our veterinary TNFα therapeutic antibody development services.
Why Choose Us?
Our team is experienced in various aspects of veterinary therapeutic antibody development, including antigen preparation, gene synthesis, animal immunization, antibody preparation, antibody engineering, and so on.
We provide heterologous antibody caninization/felinization, as well as affinity maturation services, maintaining high affinity while ensuring low immunogenicity to facilitate pharmacological research.
Our team implements stringent quality controls throughout the veterinary therapeutic antibody development process, including analysis and testing of antibody purity and stability, to maintain high quality and batch consistency.
Overexpression or dysregulation of TNFα can lead to overactivation of the immune system in companion animals, exacerbating inflammation and autoimmune diseases. Using TNFα therapeutic antibodies to modulate or inhibit its action may effectively control the pathological processes of these diseases. BioVenic offers veterinary TNFα therapeutic antibody development services, helping you explore the potential to control inflammation progression. If you are interested in our services, please do not hesitate to contact us now!
Reference
- Souza, Roberta Figueiroa, et al. "Study of tumor necrosis factor receptor in the inflammatory bowel disease." World Journal of Gastroenterology 29.18 (2023): 2733.